Last checked at 11 Apr 2024 17:13
FTSE 100 edges lower as financials drag
Lok'nStore surges to all-time high after buyout by Shurgard
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades16,417
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,050.00
Bid:
12,038.00
Ask:
12,040.00
Change:
-106.00 (-0.87%)
Spread:
2.00 (0.017%)
Open:
12,092.00
High:
12,178.00
Low:
12,010.00
Prev. Close:
12,156.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.FTSE 100 movers: Meggitt surges on merger mumbles, Carney chat hits housebuilders
Tue, 14th Jul 2015 14:29
(ShareCast News) - London markets edged lower on Tuesday, as losses from housebuilders, engineers and financials eclipsed gains made by industrial metals.As of 14:00 BST, the FTSE 100 was trading 0.2% lower at 6,727.Shares in defence and aerospace engineer Meggitt rose following a report in the Financial Times that a merger with Cobham might be on the cards. Atif Latif, director of trading at Guardian Stockbrokers, said he sees the rationale of a tie-up between the two as a defence play.AstraZeneca gained as its Iressa drug, which is used in the treatment of metastatic non-small cell lung cancer (NSCLC), was approved by the US Food and Drug Administration. Iressa is already approved in 91 countries for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive NSCLC, which is the most common type of lung cancer.Sky surged as analysts at Deutsche Bank upgraded their rating on the stock from 'hold' to 'buy' and raised estimates for 2017 by 20% more than the wider consensus. In a note to clients, Deutsche Bank said the European satellite TV giant was the best positioned in Europe to capitalise on growth areas related to online video.Meanwhile ITV was under the cosh in early trading after Deutsche Bank downgraded the stock to 'sell' from 'hold'. "We find the upside case of retransmission fees, Liberty takeout and cash returns/dividends unconvincing," said the bank.This seemed to outweigh a note from Morgan Stanley on the media sector that picked out ITV as one of its favoured stocks, while also downgrading Pearson to 'equal weight' from 'overweight'. Pearson's shares fell around 1.8% by mid afternoon.Shares in housebuilders such as Taylor Wimpey, Barratt Developments and Persimmon were all knocked lower as Mark Carney told the Treasury Select Committee that the bank rate may be headed higher a little bit sooner than markets anticipated.RisersSky (SKY) 1,115.00p +3.43%Meggitt (MGGT) 480.80p +2.19%Morrison (Wm) Supermarkets (MRW) 180.10p +1.18%Sainsbury (J) (SBRY) 265.40p +0.87%Reed Elsevier (REL) 1,094.00p +0.83%Glencore (GLEN) 252.40p +0.80%Unilever (ULVR) 2,903.00p +0.76%Direct Line Insurance Group (DLG) 348.30p +0.66%Tesco (TSCO) 213.85p +0.64%British American Tobacco (BATS) 3,639.00p +0.61%FallersTaylor Wimpey (TW.) 185.40p -3.39%Persimmon (PSN) 1,958.00p -2.78%Barratt Developments (BDEV) 624.00p -2.73%GKN (GKN) 317.10p -2.28%TUI AG Reg Shs (DI) (TUI) 1,066.00p -1.93%Weir Group (WEIR) 1,595.00p -1.73%Aberdeen Asset Management (ADN) 402.50p -1.61%Johnson Matthey (JMAT) 3,005.00p -1.48%Hammerson (HMSO) 652.50p -1.44%Marks & Spencer Group (MKS) 540.00p -1.37%
More News
11 Apr 2024 17:07
Banks weigh down Europe's STOXX 600 after ECB signals rate cuts
Outlook hike sends Ambu shares up
*Read more11 Apr 2024 15:56
London close: Stocks finish lower as ECB stands pat
(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.
Read more11 Apr 2024 11:50
LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision
(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.
Read more11 Apr 2024 08:56
TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023
(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.
Read more11 Apr 2024 08:54
LONDON MARKET OPEN: European markets mixed ahead of ECB decision
(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.
Read more11 Apr 2024 07:49
LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance
(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.
Read more11 Apr 2024 07:20
AstraZeneca to hike 2024 dividend by 7%
(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.
Read more8 Apr 2024 08:36
TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris
(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.
Read more8 Apr 2024 07:43
LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack
(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.
Read more8 Apr 2024 07:02
AstraZeneca's Enhurtu cancer gets US green light for adult patients
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.
Read more8 Apr 2024 06:53
TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.
Read more5 Apr 2024 09:42
AstraZeneca makes "breakthrough" in treating small cell lung cancer
(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.
Read more5 Apr 2024 07:50
LONDON BRIEFING: Shell to book USD600 million first-quarter write-off
(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.
Read more5 Apr 2024 07:23
AstraZeneca announces positive lung cancer treatment trial results
(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.
Read more